Search results
11 lut 2021 · Sites of cancer with the highest rates of VTE include the pancreas, kidney, ovary, lung, and stomach. 13,15 In addition to antineoplastic therapies, certain supportive care measures used in cancer treatment appear to increase the risk of VTE, including red blood cell transfusions, as well as erythropoietin-stimulating agents for managing anemia ...
10 sty 2023 · Anticoagulant treatment of VTE in cancer patients is effective but may be associated with increased bleeding. •. LMWH or DOACs are effective treatments and generally safe options for cancer-associated thrombosis. Key words. venous thromboembolism (VTE) cancer-associated thrombosis (CAT) thromboprophylaxis/prevention. anticoagulation.
Two RCTs of direct oral anticoagulants (DOACs) for the treatment of VTE in patients with cancer reported that edoxaban and rivaroxaban are effective but are linked with a higher risk of bleeding compared with low-molecular-weight heparin (LMWH) in patients with GI and potentially genitourinary cancers.
The two studies differ in the design, type of surgery (laparoscopic or open), type of cancer (colorectal cancer or gynecological cancer), comparator (placebo or LMWH), and primary outcome. Additional data from randomized clinical trials are necessary to strengthen this recommendation.
5 sie 2019 · Two RCTs of direct oral anticoagulants (DOACs) for the treatment of VTE in patients with cancer reported that edoxaban and rivaroxaban are effective but are linked with a higher risk of bleeding compared with low-molecular-weight heparin (LMWH) in patients with GI and potentially genitourinary cancers.
25 kwi 2024 · Cancer-associated venous thrombosis in adults Venous thromboembolism (VTE) primary and metastatic disease systemic anti-cancer therapy (SACT) VTE direct oral anticoagulants (DOACs) CAT Management. Declaration of Interests. The BSH paid the expenses incurred during the writing of this guidance.
7 sie 2024 · Here we discuss the risks of venous thromboembolism (VTE), which typically presents as deep vein thrombosis (DVT) and/or pulmonary embolism (PE), in adults with cancer, as well as the primary prevention of VTE in these individuals.
